Shinpoong Pharmaceutical Wins Approval to Amend Phase 3 Trial of Stroke Drug SP-8203

Bitget2026/10/22 05:43

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Shinpoong Pharmaceutical received South Korean regulatory clearance on Oct. 22, 2026, to amend its Phase 3 SP-8203 trial for acute ischemic stroke.
The amendment incorporates newly authorized thrombolytic TNK (Metalase) into the trial protocol, updating exclusion criteria and treatment procedures.
The ongoing, placebo-controlled study plans to enroll 852 patients to assess SP-8203’s safety and efficacy alongside standard thrombolytic treatment.
Earlier Phase 2 safety and efficacy findings supported advancing the treatment into the larger study.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shinpoong Pharmaceutical Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261022800250), on October 22, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Shinpoong Pharmaceutical Wins Approval to Amend Phase 3 Trial of Stroke Drug SP-8203

You may also like

Crypto prices